Physician profile
Michael E Burnett
NPI 1730169418
$3,389.19
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $1,227 · 2021: $1,009.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.62 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $602.29 | 2019-2021 | |
| Grifols USA, LLC | $482.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $363.71 | 2019-2021 | |
| Mylan Specialty L.P. | $198.23 | 2019-2021 | |
| Genzyme Corporation | $157.98 | 2019-2021 | |
| Insmed, INC. | $130.59 | 2019 | |
| Genentech USA, INC. | $91.25 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $86.00 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $74.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $58.23 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $53.79 | 2020 | |
| Jazz Pharmaceuticals INC. | $40.53 | 2019-2020 | |
| United Therapeutics Corporation | $35.92 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $33.82 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $30.00 | 2019 | |
| Bard Peripheral Vascular, INC. | $25.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.51 | 2020 | |
| Melinta Therapeutics, LLC | $21.27 | 2021 | |
| Resmed Corp | $20.71 | 2019 | |
| Advanced Respiratory, INC | $18.77 | 2020 | |
| Circassia INC. | $18.70 | 2019 | |
| Philips North America LLC | $17.44 | 2019 | |
| La Jolla Pharmaceutical Company | $15.23 | 2020 | |
| Electromed, INC. | $14.97 | 2021 | |
| Shire North American Group INC | $13.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.